

Athena announces the Approval of its DDS facility by Saudi Food & Drug Authority - SFDA

September 2024 :

Athena Drug Delivery Solutions Private, Ltd a subsidiary of Athena Pharmaceutiques SA France, a leading innovator in the pharmaceutical industry, is delighted to announce the successful approval of its Athena Drug Delivery Solutions Pvt Ltd. (DDS), India site in Kingdom of Saudi Arabia by SFDA, marking a significant milestone in expanding its global presence. Furthermore, we are elated to share this approval opens new avenues for us to collaborate with major industry players in GCC.

The Saudi Arabia pharmaceutical market stands as a rapidly expanding sector within the Saudi economy, estimated to be valued at US\$ 12.60 billion in 2024 and expected to exhibit a CAGR of 7.6% during the forecast period (2024-2030).

Mr. Alexandre Williams, President and Mr. Mahendra Chaudhari, Managing Director, said, "We are extremely enthusiastic about the approval of our manufacturing plant in Kingdom of Saudi Arabia which is following our latest Licensing deal and partnership in GCC and specifically with KSA," "We expect our first launches in 2025 and we hope to develop and increase our cooperation with Saudi companies".

About Athena:

Athena is engaged in Licensing and Development model supported by its Manufacturing facilities and R&D Centre in France and India approved by EU GMP, Brazil, Canada, Russia, KSA, China and many others Pharmemerging markets. Athena's 450 Specialized Staff are focus on value added products for mature and emerging markets.

Athena provides product lifecycle management solutions for Oral Solids based on its proprietary technology's platforms viz., Acetyl Cysteine Stick w/wo water, Bisoprolol Aspirin, Bilastine ODT, Etifoxine, Fenofibrate, Levoceterizine ODT, Ketorolac Sublingual, Ketoprofen-Omeprazole, Lisdexamphetamine ODT, Mesalazine High Dose Sachets, Ondansetron ODT, Paracetamol Effervescent Tablet, Secnidazole High Dose Sachet, Racecadotril Sachets, Tramadol +Paracetamol ODT and Zolpidem ODT and Sublingual. These products are already marketed by leading companies across geographies or are under registration.